Bone Biologics (BBLG) Short term Debt (2013 - 2017)

Bone Biologics (BBLG) has 5 years of Short term Debt data on file, last reported at $12.9 million in Q3 2017.

• Short term Debt for Q3 2017 came in at $12.9 million, up 43.33% year-over-year; the trailing twelve-month figure through Sep 2017 was $12.9 million (up 43.33% YoY), and the FY2016 annual result was $1.2 million, down 40.0% from the prior year.
• Short term Debt climbed to $12.9 million in Q3 2017 per BBLG's latest filing, from $12.2 million in the prior quarter.
• Over five years, Short term Debt peaked at $12.9 million in Q3 2017 and troughed at $41300.0 in Q4 2013.
• A 5-year average of $6.5 million and a median of $7.0 million in 2015 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2014 and 2015: Short term Debt jumped 12006.54% in 2014, then plunged 60.0% in 2015.
• A 5-year view of Short term Debt shows it stood at $41300.0 in 2013, then jumped by 12006.54% to $5.0 million in 2014, then sank by 60.0% to $2.0 million in 2015, then plunged by 40.0% to $1.2 million in 2016, then soared by 975.0% to $12.9 million in 2017.
• Business Quant data shows BBLG's Short term Debt at $12.9 million in Q3 2017, $12.2 million in Q2 2017, and $12.2 million in Q1 2017.